Search
lumiracoxib (Prexige)
approved in the UK, but not yet in the US.) [1,2,3]
Indications:
- osteoarthritis
Dosage:
- 100 mg PO QD
Adverse effects:
- elevated serum transaminases
- lower risk of upper GI bleeding & small bowel injury than non-selective NSIADs [3]
Mechanism of action:
- highly-selective cyclooxygenase-2/COX-2 inhibitor
Interactions
drug interactions
drug adverse effects (more general classes)
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
cyclooxygenase-2 (COX-2) specific inhibitor
Properties
INHIBITS: cyclooxygenase-2
Database Correlations
PUBCHEM cid=151166
References
- Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M,
Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A,
Hawkey CJ; TARGET Study Group.
Comparison of lumiracoxib with naproxen and ibuprofen in the
Therapeutic Arthritis Research and Gastrointestinal Event Trial
(TARGET), reduction in ulcer complications: randomised
controlled trial.
Lancet. 2004 Aug 21;364(9435):665-74.
PMID: 15325831
- Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW,
Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M,
Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P,
Hawkey CJ, Chesebro JH; TARGET Study Group.
Comparison of lumiracoxib with naproxen and ibuprofen in the
Therapeutic Arthritis Research and Gastrointestinal Event Trial
(TARGET), cardiovascular outcomes: randomised controlled trial.
Lancet. 2004 Aug 21;364(9435):675-84.
PMID: 15325832
- Journal Watch 24(19):149, 2004
- Hawkey CJ et al.
Less small-bowel injury with lumiracoxib compared with naproxen
plus omeprazole.
Clin Gastroenterol Hepatol 2008 May; 6:536.
PMID: 18242145